In Vivo CRO Market Growth, Size, Trends Analysis - By Model Type, By Modality, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

In Vivo CRO Market Introduction and Overview

According to SPER market research, 'Global In Vivo CRO Market Size- By Model Type, By Modality, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global In Vivo CRO Market is predicted to reach 11.47 billion by 2034 with a CAGR of 8.38%.

In vivo CRO services are a type of research service given by Contract Research Organisations (CROs) that includes tests conducted on living organisms, often animals, to examine the safety and efficacy of innovative medicines. These services frequently involve preclinical investigations, such as toxicology, pharmacokinetics, and efficacy studies, which are used to promote the development and regulatory approval of new medications or medical devices.

Restraints: The high cost of drug development has hampered market growth. Developing novel medication therapies is an extremely expensive procedure. This includes everything from doing basic research and clinical trials to securing regulatory approval. Pharmaceutical companies are under intense pressure to maximise their return on investment for new treatments. These factors are projected to limit the growth of the in vivo CRO market over the forecast period.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Model Type, By Modality, By Indication

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered IQVIA Inc, Crown Bioscience, Taconic Biosciences, Inc, PsychoGenics Inc, Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc.

Global In Vivo CRO Market Segmentation:

By Model Type: Based on the Model Type, Global In Vivo CRO Market is segmented as; Rodent Based, Non-Rodent Based.

By Modality: Based on the Modality, Global In Vivo CRO Market is segmented as; Small Molecule, Large Molecule.

By Indication: Based on the Indication, Global In Vivo CRO Market is segmented as; Oncology, CNS Conditions, Diabetes, Obesity, Pain management, Autoimmune/inflammation conditions, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25131

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global In Vivo CRO Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global In Vivo CRO Market

7. Global In Vivo CRO Market, By Model Type (USD Million) 2021-2034

7.1. Rodent based
- 7.1.1. Rat Models
- 7.1.2. Mice Models
- 7.1.3. Others
7.2. Non-Rodent based

8. Global In Vivo CRO Market, By Modality (USD Million) 2021-2034

8.1. Small Molecules
8.2. Large Molecules
- 8.2.1. Cell & Gene Therapy
- 8.2.1. CAR T-cell therapies
- 8.2.1. CAR-NK cell therapy
- 8.2.1. TCR-T cell therapy
- 8.2.1. Other
- 8.2.2. RNA Therapy
- 8.2.3. Others

9. Global In Vivo CRO Market, By Indication (USD Million) 2021-2034

9.1. Oncology
- 9.1.1. Blood cancer
- 9.1.2. Solid tumor
- 9.1.3. Others
9.2. CNS Conditions
- 9.2.1. Epilepsy
- 9.2.2. Parkinson's disease
- 9.2.3. Huntington's disease
- 9.2.4. Stroke
- 9.2.5. Muscular Dystrophy
- 9.2.6. Alzheimer's Disease
- 9.2.7. Traumatic brain injury
- 9.2.8. Amyotrophic lateral sclerosis (ALS)
- 9.2.9. Spinal Muscular Atrophy
- 9.2.10. Muscle regeneration
- 9.2.11. Other Neurodevelopment Disorders
9.3. Diabetes
9.4. Obesity
9.5. Pain management
- 9.5.1. Chronic pain
- 9.5.2. Acute pain
9.6. Autoimmune/inflammation conditions
- 9.6.1. Rheumatoid Arthritis
- 9.6.2. Multiple Sclerosis
- 9.6.3. Osteoarthritis
- 9.6.4. Irritable Bowel Syndrome
- 9.6.5. Others
9.7. Others

10. Global In Vivo CRO Market, (USD Million) 2021-2034

10.1. Global In Vivo CRO Market Size and Market Share

11. Global In Vivo CRO Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. IQVIA Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Crown Bioscience
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Taconic Biosciences, Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. PsychoGenics Inc
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Evotec
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Janvier Labs
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Biocytogen
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. GemPharmatech
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Charles River Laboratories
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Icon Plc
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others